What is Wegovy
Wegovy is a medicine with the active ingredient semaglutide. It is used as an aid in losing weight and maintaining weight in adults with obesity (BMI ≥ 30) or overweight (BMI 27–30) with weight-related health problems, such as high blood pressure, sleep apnea, or high cholesterol.
Within The Body Clinic, a doctor assesses during the consultation whether treatment with medication is suitable within a medical trajectory for weight management. More information about our medical approach can be found in our treatment program.
Wegovy is also available as a tablet that you take once a day. The Wegovy pill was approved in the European Union in July 2026. It is expected to become available in the Netherlands in November 2026, but this date has not yet been confirmed. Read everything about the Wegovy pill.
Dose escalation
Treatment with Wegovy starts with a low dose of 0.25 mg per week. The dose can then be increased step by step, depending on the effect and how well you tolerate the medication. There are at least four weeks between two dose increases. If the dose is increased every four weeks, the schedule looks like this:
| Month | Dose once a week |
|---|---|
| Month 1 | 0.25 mg |
| Month 2 | 0.5 mg |
| Month 3 | 1.0 mg |
| Month 4 | 1.7 mg |
| Month 5 | 2.4 mg |
| Month 6 | 7.2 mg |
The 7.2 mg dose is only intended for people who need additional weight loss after at least four weeks on 2.4 mg. Your doctor will assess whether this makes sense for you.
How does Wegovy work?
Wegovy mimics the body's own hormone GLP-1. Your gut naturally produces this hormone after eating. It signals to your brain that you have eaten enough. Semaglutide works much longer than the natural hormone, so one injection per week is enough.
What it does in your body
- Less hunger and feeling full sooner. GLP-1 sends a satiety signal to the brain. Many people also notice less 'food noise', the constant thinking about food.
- Slower gastric emptying. Food stays in your stomach longer, so you feel full for longer.
- Better blood sugar control. The pancreas releases more insulin when your blood sugar rises, and the release of glucagon decreases.
Wegovy is not a miracle cure. It works best combined with changes in diet and exercise, under the supervision of a doctor.
Instructions for using Wegovy
Wegovy comes as a single-use pre-filled injection pen. Always read the package leaflet or ask your doctor or pharmacist for an explanation.
Important:
- One injection per week, on a fixed day.
- The dose is increased gradually, starting with 0.25 mg per week.
- Each pen contains one fixed dose and is discarded after use.
Injection site
- Under the skin of the abdomen, thigh or upper arm.
- Do not inject into a vein or muscle.
- Always have a doctor or nurse demonstrate the first use.
Storage
- In the refrigerator (2–8 °C), do not freeze, protect from light.
- Outside the refrigerator: up to 28 days below 30 °C.
Read step by step how to inject Wegovy.
Semaglutide
Semaglutide is the active ingredient in Wegovy and is produced by Novo Nordisk. It belongs to the class of incretin mimetics and mimics the action of the natural gut hormone GLP-1 (glucagon-like peptide-1). After a meal, this hormone is normally released into the intestine. It stimulates the pancreas to release more insulin when blood sugar rises, reduces glucagon secretion from the liver, slows gastric emptying, and provides a stronger feeling of satiety in the brain. Through this combined action, semaglutide helps the body regulate blood sugar levels and, with a medical indication, supports weight loss and weight maintenance when used in combination with a healthy lifestyle and guidance from a doctor.
Wegovy and Weight Loss
Wegovy has been studied in randomized clinical trials regarding its effect on body weight in adults with obesity or overweight in combination with lifestyle advice (diet and exercise). These studies showed that semaglutide, combined with guidance and lifestyle adjustments, led to a substantial and clinically relevant weight loss in many participants compared to placebo.
Briefly explained: participants followed dietary and exercise advice and received a weekly injection of semaglutide or placebo. On average, body weight decreased more significantly in the semaglutide group. In the STEP 1 study, the following results were found after 68 weeks of treatment:
Results after 68 weeks (STEP 1 study)
| Treatment group | Average weight loss | ≥ 5% | ≥ 10% | ≥ 15% |
|---|---|---|---|---|
| Semaglutide 7.2 mg once a week | −21% | 86% | 69% | 50% |
| Placebo + lifestyle guidance | −2.4% | 31% | 12% | 5% |
The effect gradually builds up during treatment. Results may vary per person; medication does not work for everyone and can cause side effects. Always read the package leaflet or SmPC and discuss expectations and risks with your treating physician.


